Sugammadex 1 mg/kg

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, Poitiers University Hospital, Universitas Padjadjaran

Conditions

AnesthesiaMorbid ObesityNeuromuscular Blocking AgentsRecovery TimeReversal of Neuromuscular Blockade

Phase 1

Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade

RecruitingNCT06794450

Universitas PadjadjaranNeuromuscular Blocking Agents, Recovery Time, Reversal of Neuromuscular Blockade

Start: 2024-11-05End: 2025-02-28Target: 60Updated: 2025-01-28

Phase 2

Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients

CompletedNCT02545595

Poitiers University HospitalMorbid Obesity

Start: 2012-05-31Updated: 2016-10-12

Phase 3

Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)

CompletedNCT00421148

Merck Sharp & Dohme LLCAnesthesia

Start: 2005-05-30End: 2006-06-02Updated: 2019-01-28